To outcompete China, unhandcuff America’s biotech innovators
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
Why It Matters
This story touches on united-states, china, outcompete — topics readers are actively tracking. Review and add editorial context before publishing.
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
(Original synthesis pending human/AI review — generated by the stub provider from the source excerpt only, not copied verbatim from the full article.)
Original source: The Hill
Related Stories
Graham wins GOP nod in South Carolina Senate primary runoff for late brother’s seat
David Scott’s daughter defeated in Georgia House special election for open seat
Dolly Parton died following ‘brief battle with cancer’
